Literature DB >> 2321782

Understanding pharmacokinetics and pharmacodynamics through computer stimulation: I. The comparative clinical profiles of fentanyl and alfentanil.

W F Ebling1, E N Lee, D R Stanski.   

Abstract

The authors have used computer simulation to examine the time course of the plasma concentration, estimated effect site concentration, and the intensity of the central nervous system (CNS) effect of fentanyl and alfentanil. The simulations were performed over a range of clinically equivalent doses. Simulations of the changes in the processed electroencephalogram (EEG) was used as a reflection of drug induced CNS effect. The simulations reveal that the rate of equilibration between effect site and plasma concentrations can explain differences in the clinical time course of drug effect between these opioids. The onset of fentanyl EEG drug effect is delayed relative to alfentanil and the duration of action is longer. Pharmacokinetic differences do not explain the disparity seen in the time courses of EEG drug effect. Alfentanil and fentanyl have similar plasma disposition curves during the first 90 min. The concentrations at the effect site are, however, quite different. The simulations illustrate how fentanyl's slow blood:brain equilibration can dampen the rate of rise and fall of effect site concentrations. As a mechanism for terminating effect, redistribution of opioid from effect site to other body regions is less relevant for fentanyl compared with that for alfentanil. The evanescent clinical effects of alfentanil can be explained by the rapid blood:brain equilibration. Computer simulation is a useful tool for revealing relevant determinants of the complex relationship between dose and the time course of effect.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2321782     DOI: 10.1097/00000542-199004000-00013

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  9 in total

Review 1.  Pharmacokinetics and pharmacodynamics for the clinician.

Authors:  D R Stanski
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

2.  Tissue distribution of fentanyl and alfentanil in the rat cannot be described by a blood flow limited model.

Authors:  S Björkman; D R Stanski; H Harashima; R Dowrie; S R Harapat; D R Wada; W F Ebling
Journal:  J Pharmacokinet Biopharm       Date:  1993-06

3.  Convergence of direct and indirect pharmacodynamic response models.

Authors:  W J Jusko; H C Ko; W F Ebling
Journal:  J Pharmacokinet Biopharm       Date:  1995-02

Review 4.  Pharmacokinetic-pharmacodynamic relationships in phase I/phase II of drug development.

Authors:  A Van Peer; E Snoeck; M L Huang; J Heykants
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jan-Mar       Impact factor: 2.441

Review 5.  Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option.

Authors:  Mellar P Davis; Gavril Pasternak; Bertrand Behm
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

6.  EEG Predicts movement response to surgical stimuli during general anesthesia with combinations of isoflurane, 70% N2O, and fentanyl.

Authors:  R C Dutton; W D Smith; N T Smith
Journal:  J Clin Monit       Date:  1996-03

7.  Competitive substrates for P-glycoprotein and organic anion protein transporters differentially reduce blood organ transport of fentanyl and loperamide: pharmacokinetics and pharmacodynamics in Sprague-Dawley rats.

Authors:  Iman A Elkiweri; Yan Ling Zhang; Uwe Christians; Ka-Yun Ng; Martha C Tissot van Patot; Thomas K Henthorn
Journal:  Anesth Analg       Date:  2009-01       Impact factor: 5.108

Review 8.  Pharmacokinetic-pharmacodynamic relationships for opioids in balanced anaesthesia.

Authors:  H J Lemmens
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

9.  Buprenorphine: Far Beyond the "Ceiling".

Authors:  Rosmara Infantino; Consalvo Mattia; Pamela Locarini; Antonio Luigi Pastore; Sabatino Maione; Livio Luongo
Journal:  Biomolecules       Date:  2021-05-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.